Table 1.
Changes in QICA Score and Clinical Quality Measures Between Baseline and Follow-up
| Measure | Baseline, Mean (SD) | Follow-Up, Mean (SD) | Change, Mean (95% CI) | P Valuea |
|---|---|---|---|---|
| QICA score b | ||||
| Total score | 6.45 (1.39) | 7.88 (1.4) | 1.44 (1.20-1.68) | <.001 |
| HLC subscore | <.001 | |||
| 1. Embed clinical evidence | 6.95 (2.29) | 8.32 (1.74) | 1.37 (1.01-1.73) | <.001 |
| 2. Utilize data to improve Performance | 4.98 (2.43) | 6.97 (2.40) | 1.98 (1.58-2.39) | <.001 |
| 3. Establish regular QI processes | 5.14 (2.20) | 7.39 (2.16) | 2.25 (1.85-2.65) | <.001 |
| 4. Identify at-risk patients | 5.46 (1.86) | 7.06 (1.85) | 1.60 (1.27-1.93) | <.001 |
| 5. Define roles and responsibilities | 6.96 (1.80) | 8.15 (1.80) | 1.20 (0.90-1-.51) | <.001 |
| 6. Improve patient self-management | 7.44 (1.82) | 8.51 (1.78) | 1.08 (0.78-1.39) | <.001 |
| 7. Link patients to outside resources | 8.20 (1.64) | 8.99 (1.40) | 0.79 (0.52-1.07) | <.001 |
| Clinical Quality Measure c | ||||
| Aspirin use, % | 66.81 (16.61) | 70.79 (13.20) | 3.98 (1.17-6.79) | .006 |
| Blood pressure control, % | 61.48 (12.00) | 64.84 (11.48) | 3.36 (1.44-5.27) | .001 |
| Smoking screening/cessation counseling, % | 73.78 (22.88) | 81.27 (21.26) | 7.49 (4.21-10.77) | <.001 |
HLC = high-leverage change; QI = quality improvement; QICA = Quality Improvement Capacity Assessment.
aFrom a t test that tested for differences of the mean change from zero.
bLimited to clinics that completed both QICA surveys (N = 165). Possible range of total score and of each HLC subscore is 1 to 12 points; higher scores denote greater QI capacity.
cPercent of the eligible patient population achieving the measure. Limited to clinics that completed both QICA surveys and reported clinical quality measures in both 2015 and 2017 (N = 130 for aspirin use, N = 161 for blood pressure control, and N = 130 for smoking screening/cessation counseling).